Novo Nordisk A/S (NVO)
112.12
+3.69 (+3.40%)
USD |
NYSE |
Jun 24, 16:00
112.10
-0.02 (-0.02%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 253.98B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 38.44% |
| Valuation | |
| PE Ratio | 33.38 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 11.07 |
| Price to Book Value | 25.43 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 1.022 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.3829 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 28.40% |
News
Headline
Wire
Time (ET)
Yahoo
06/23 08:00
SA Breaking News
06/23 06:03
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 08/04/2022 | -- | Results | Q2 2022 | -- | 0.83 | -- | |
| 08/04/2022 | -- | Earnings Call | Q2 2022 | -- | -- | -- | |
| 02/02/2022 | -- | Results | Q4 2021 | 0.72 | 0.72 | 0.74% | |
| 02/02/2022 | 07:00 EST | Earnings Call | Q4 2021 | -- | -- | -- | |
| 11/03/2021 | -- | Results | Q3 2021 | -- | 0.80 | -- | |
| 11/03/2021 | 08:00 EST | Earnings Call | Q3 2021 | -- | -- | -- | |
| 08/06/2021 | 07:00 EST | Earnings Call | Q2 2021 | -- | -- | -- | |
| 08/04/2021 | -- | Results | Q2 2021 | 0.84 | 0.76 | 10.47% |
*Estimated Date/Time
Earnings
Profile
Edit
| With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders. |
| URL | https://www.novonordisk.com |
| Investor Relations URL | https://www.novonordisk.com/investors.html |
| HQ State/Province | N/A |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Large Cap/Growth |
| Next Earnings Release | Aug. 04, 2022 |
| Last Earnings Release | Feb. 02, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Mar. 25, 2022 |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | 1.578 |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.99 |
| Yield to Sector | 0.661 |
| Yield to Industry | 2.022 |
| Last Dividend Amt. | 1.022 |
| Dividend Frequency | Semi-Annually |
| Last Ex-Dividend Date | Mar. 25, 2022 |
| Yield (TTM) | 1.40% |
| Forward Yield | 1.40% |
| Payout Ratio | 46.76% |
| Cash Payout Ratio | 38.81% |
| Consistent Payer (5Y) |
|
| Consistent Growth (5Y) | No |
Risk Info
Total Returns Comparison
Annual Total Returns Versus Peers
As of June 24, 2022.
Fundamentals
| Revenue (TTM) | 23.24B |
| Total Expenses (TTM) | 13.44B |
| Net Income (TTM) | 7.705B |
| Total Assets (Quarterly) | 29.58B |
| Total Liabilities (Quarterly) | 19.60B |
| Shareholders Equity (Quarterly) | 9.987B |
| Cash from Operations (TTM) | 10.49B |
| Cash from Investing (TTM) | -4.752B |
| Cash from Financing (TTM) | -4.597B |
Ratings
Profile
Edit
| With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders. |
| URL | https://www.novonordisk.com |
| Investor Relations URL | https://www.novonordisk.com/investors.html |
| HQ State/Province | N/A |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Large Cap/Growth |
| Next Earnings Release | Aug. 04, 2022 |
| Last Earnings Release | Feb. 02, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Mar. 25, 2022 |
Risk Info
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Top Fund Holders
| Symbol | Dollars Invested | % Weight |
|---|---|---|
| LIFE.TO | 11.38M USD | 4.89% |
| PPH | 24.72M USD | 4.83% |
| PJHRX | 75.86M USD | 4.46% |
| AMIGX | 110.64M USD | 3.49% |
| THW | 17.05M USD | 3.09% |
| HRINX | 77.40M USD | 1.88% |
| CHW | 11.83M USD | 1.59% |
| LGLQX | 98.52M USD | 1.48% |
| ETG | 22.54M USD | 1.27% |
| DFALX | 57.91M USD | 1.06% |
| AVDE | 11.04M USD | 0.80% |
| DFIEX | 169.69M USD | 0.54% |
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Morningstar | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| NVO Tweets |